Comirnaty Gives Booster Shot To Pfizer Q3 Sales
Vaccine Drives Revenues Up 130%
Executive Summary
The company increased its guidance for sales of the COVID-19 vaccine again, to $36bn, though many other products’ sales were close to or below analyst expectations.
You may also be interested in...
J.P. Morgan Day 2: What's Next For Pharma, From Alzheimer's To Omicron
Daily notebook from the virtual J.P. Morgan Healthcare Conference: Alzheimer's rivals Roche and Lilly address their attempts at a different launch for their anti-amyloid therapies than Biogen's Aduhelm. GSK is buoyed by sotrovimab's efficacy against Omicron, BioNTech looks to the future of mRNA and Sanofi, Amgen and AbbVie defend their growth strategies.
J.P. Morgan Day 2: What's Next For Pharma, From Alzheimer's To Omicron
Daily notebook from the virtual J.P. Morgan Healthcare Conference: Alzheimer's rivals Roche and Lilly address their attempts at a different launch for their anti-amyloid therapies than Biogen's Aduhelm. GSK is buoyed by sotrovimab's efficacy against Omicron, BioNTech looks to the future of mRNA and Sanofi, Amgen and AbbVie defend their growth strategies.
COVID-19 Products Had Strong 2021, But Omicron Casts Shadow Over 2022
Evidence that the new variant dulls drugs and vaccines’ efficacy creates uncertainty for 2022, but new products are in the wings.